Literature DB >> 19788390

Optimized adeno-associated virus (AAV)-protein phosphatase-5 helper viruses for efficient liver transduction by single-stranded AAV vectors: therapeutic expression of factor IX at reduced vector doses.

Giridhara R Jayandharan1, Li Zhong, Brandon K Sack, Angela E Rivers, Mengxin Li, Baozheng Li, Roland W Herzog, Arun Srivastava.   

Abstract

Abstract Our studies have shown that coinjection of conventional single-stranded adeno-associated virus 2 (ssAAV2) vectors carrying the enhanced green fluorescent protein (EGFP) gene with self-complementary (sc) AAV2-T cell protein tyrosine phosphatase (TC-PTP) and scAAV2-protein phosphatase-5 (PP5) vectors resulted in an approximately 16-fold increase in EGFP expression in primary murine hepatocytes in vivo [Jayandharan, G.R., Zhong, L., Li, B., Kachniarz, B., and Srivastava, A. (2008). Gene Ther. 15, 1287-1293]. In the present studies, this strategy was further optimized to achieve transgene expression at reduced vector/helper virus doses. These included the use of scAAV helper viruses containing (1) hepatocyte-specific promoters, (2) tyrosine-mutant AAV2 capsids, and (3) additional AAV serotype vectors known to efficiently transduce hepatocytes. The hepatocyte-specific transthyretin (TTR) promoter was approximately 6- to 7-fold more efficient than the Rous sarcoma virus (RSV) promoter; tyrosine-mutant AAV2 capsids were approximately 6- to 11-fold more efficient than the wild-type AAV2 capsids; and the AAV8 serotype helper virus was approximately 16-fold more efficient than AAV2 serotype helper virus. With these modifications, the vector dose of the helper virus could be further reduced by approximately 50-fold. Last, coadministration of scAAV8-PP5 helper virus increased coagulation factor IX expression from an ssAAV2 vector by approximately 7- to 10-fold, thereby achieving therapeutic levels at lower vector doses. No adverse effect on hepatocytes was observed under any of these experimental conditions. The strategy presented here should be adaptable to any ssAAV transgene cassette and, specifically, liver-directed applications of ssAAV2 vectors containing larger genes that cannot be encapsidated in scAAV vectors.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 19788390      PMCID: PMC2865358          DOI: 10.1089/hum.2009.100

Source DB:  PubMed          Journal:  Hum Gene Ther        ISSN: 1043-0342            Impact factor:   5.695


  65 in total

1.  Rapid uncoating of vector genomes is the key to efficient liver transduction with pseudotyped adeno-associated virus vectors.

Authors:  Clare E Thomas; Theresa A Storm; Zan Huang; Mark A Kay
Journal:  J Virol       Date:  2004-03       Impact factor: 5.103

2.  Sustained phenotypic correction of canine hemophilia A using an adeno-associated viral vector.

Authors:  Ciaran D Scallan; David Lillicrap; Haiyan Jiang; Xiaobing Qian; Susannah L Patarroyo-White; Amy E Parker; Tongyao Liu; Joseph Vargas; Dea Nagy; Sharon K Powell; J Fraser Wright; Patricia V Turner; Shawn J Tinlin; Sandra E Webster; Alan McClelland; Linda B Couto
Journal:  Blood       Date:  2003-05-08       Impact factor: 22.113

3.  Induction of immune tolerance to coagulation factor IX antigen by in vivo hepatic gene transfer.

Authors:  Federico Mingozzi; Yi-Lin Liu; Eric Dobrzynski; Antje Kaufhold; Jian Hua Liu; YuQin Wang; Valder R Arruda; Katherine A High; Roland W Herzog
Journal:  J Clin Invest       Date:  2003-05       Impact factor: 14.808

4.  A single adeno-associated virus (AAV)-murine factor VIII vector partially corrects the hemophilia A phenotype.

Authors:  R Sarkar; W Xiao; H H Kazazian
Journal:  J Thromb Haemost       Date:  2003-02       Impact factor: 5.824

5.  Adeno-associated virus type 2-mediated gene transfer: role of cellular T-cell protein tyrosine phosphatase in transgene expression in established cell lines in vitro and transgenic mice in vivo.

Authors:  Keyun Qing; Weiming Li; Li Zhong; Mengqun Tan; Jonathan Hansen; Kirsten A Weigel-Kelley; Linyuan Chen; Mervin C Yoder; Arun Srivastava
Journal:  J Virol       Date:  2003-02       Impact factor: 5.103

6.  AAV-mediated factor IX gene transfer to skeletal muscle in patients with severe hemophilia B.

Authors:  Catherine S Manno; Amy J Chew; Sylvia Hutchison; Peter J Larson; Roland W Herzog; Valder R Arruda; Shing Jen Tai; Margaret V Ragni; Arthur Thompson; Margareth Ozelo; Linda B Couto; Debra G B Leonard; Frederick A Johnson; Alan McClelland; Ciaran Scallan; Erik Skarsgard; Alan W Flake; Mark A Kay; Katherine A High; Bertil Glader
Journal:  Blood       Date:  2002-12-19       Impact factor: 22.113

7.  Phase I trial of intramuscular injection of a recombinant adeno-associated virus alpha 1-antitrypsin (rAAV2-CB-hAAT) gene vector to AAT-deficient adults.

Authors:  Terence R Flotte; Mark L Brantly; L Terry Spencer; Barry J Byrne; Carolyn T Spencer; Dawn J Baker; Margaret Humphries
Journal:  Hum Gene Ther       Date:  2004-01       Impact factor: 5.695

8.  Rapid and highly efficient transduction by double-stranded adeno-associated virus vectors in vitro and in vivo.

Authors:  Z Wang; H-I Ma; J Li; L Sun; J Zhang; X Xiao
Journal:  Gene Ther       Date:  2003-12       Impact factor: 5.250

9.  Novel adeno-associated viruses from rhesus monkeys as vectors for human gene therapy.

Authors:  Guang-Ping Gao; Mauricio R Alvira; Lili Wang; Roberto Calcedo; Julie Johnston; James M Wilson
Journal:  Proc Natl Acad Sci U S A       Date:  2002-08-21       Impact factor: 11.205

10.  Improved transduction of primary murine hepatocytes by recombinant adeno-associated virus 2 vectors in vivo.

Authors:  L Zhong; W Li; Z Yang; L Chen; Y Li; K Qing; K A Weigel-Kelley; M C Yoder; W Shou; A Srivastava
Journal:  Gene Ther       Date:  2004-07       Impact factor: 5.250

View more
  21 in total

Review 1.  Self-complementary adeno-associated viral vectors for gene therapy of hemophilia B: progress and challenges.

Authors:  Deepak Raj; Andrew M Davidoff; Amit C Nathwani
Journal:  Expert Rev Hematol       Date:  2011-10       Impact factor: 2.929

2.  Adeno-Associated Virus: The Naturally Occurring Virus Versus the Recombinant Vector.

Authors:  Arun Srivastava
Journal:  Hum Gene Ther       Date:  2016-01       Impact factor: 5.695

3.  MicroRNA-206 prevents the pathogenesis of hepatocellular carcinoma by modulating expression of met proto-oncogene and cyclin-dependent kinase 6 in mice.

Authors:  Heng Wu; Junyan Tao; Xiaolei Li; Tianpeng Zhang; Lei Zhao; Yao Wang; Lei Zhang; Jun Xiong; Zhi Zeng; Na Zhan; Clifford J Steer; Li Che; Mingjie Dong; Xiaomei Wang; Junqi Niu; Zhuoyu Li; Guiqing Yan; Xin Chen; Guisheng Song
Journal:  Hepatology       Date:  2017-10-30       Impact factor: 17.425

4.  A negative feedback loop between microRNA-378 and Nrf1 promotes the development of hepatosteatosis in mice treated with a high fat diet.

Authors:  Tianpeng Zhang; Xiaoling Zhao; Clifford J Steer; Guiqin Yan; Guisheng Song
Journal:  Metabolism       Date:  2018-04-03       Impact factor: 8.694

5.  MicroRNA-378 promotes hepatic inflammation and fibrosis via modulation of the NF-κB-TNFα pathway.

Authors:  Tianpeng Zhang; Junjie Hu; Xiaomei Wang; Xiaoling Zhao; Zhuoyu Li; Junqi Niu; Clifford J Steer; Guohua Zheng; Guisheng Song
Journal:  J Hepatol       Date:  2018-09-13       Impact factor: 25.083

6.  Human hepatocyte growth factor receptor is a cellular coreceptor for adeno-associated virus serotype 3.

Authors:  Chen Ling; Yuan Lu; Jasmine K Kalsi; Giridhara R Jayandharan; Baozheng Li; Wenqin Ma; Binbin Cheng; Samantha W Y Gee; Katherine E McGoogan; Lakshmanan Govindasamy; Li Zhong; Mavis Agbandje-McKenna; Arun Srivastava
Journal:  Hum Gene Ther       Date:  2010-12       Impact factor: 5.695

7.  An adeno-associated virus vector efficiently and specifically transduces mouse skeletal muscle.

Authors:  Isao Murakami; Takamasa Takeuchi; Mayuyo Mori-Uchino; Seiichiro Mori; Takuma Fujii; Daisuke Aoki; Keiichi Nakagawa; Tadahito Kanda
Journal:  Mol Biotechnol       Date:  2011-09       Impact factor: 2.695

8.  A simple method to increase the transduction efficiency of single-stranded adeno-associated virus vectors in vitro and in vivo.

Authors:  Wenqin Ma; Baozheng Li; Chen Ling; Giridhara R Jayandharan; Arun Srivastava; Barry J Byrne
Journal:  Hum Gene Ther       Date:  2011-05       Impact factor: 5.695

9.  Adeno-associated virus capsid proteins may play a role in transcription and second-strand synthesis of recombinant genomes.

Authors:  Maxim Salganik; Fikret Aydemir; Hyun-Joo Nam; Robert McKenna; Mavis Agbandje-McKenna; Nicholas Muzyczka
Journal:  J Virol       Date:  2013-11-06       Impact factor: 5.103

10.  Development of Novel Recombinant AAV Vectors and Strategies for the Potential Gene Therapy of Hemophilia.

Authors:  Li Zhong; Giridhara R Jayandharan; George V Aslanidi; Sergei Zolotukhin; Roland W Herzog; Arun Srivastava
Journal:  J Genet Syndr Gene Ther       Date:  2012-01-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.